Regulating billions of blood platelets: Glycans and beyond

Blood

Volumn 126, Issue 16, 2015, Pages 1877-1884

  Grozovsky, Renata ^a   Giannini, Silvia ^a   Falet, Hervé ^a   Hoffmeister, Karin M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASHWELL MORRELL RECEPTOR; GLYCAN DERIVATIVE; INTERLEUKIN 6 RECEPTOR; RECEPTOR; THROMBOPOIETIN; UNCLASSIFIED DRUG; POLYSACCHARIDE;

APOPTOSIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW; THROMBOCYTE; THROMBOCYTE COUNT; THROMBOCYTE LIFESPAN; THROMBOCYTE METABOLISM; THROMBOCYTE PRESERVATION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPOIESIS; CELL AGING; CYTOLOGY; METABOLISM; PHYSIOLOGY;

BLOOD PLATELETS; CELL AGING; HUMANS; POLYSACCHARIDES; PROTEIN PROCESSING, POST-TRANSLATIONAL; THROMBOPOIESIS;

EID: 84944244941     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-01-569129     Document Type: Review

References (104)

1. McCarty JM, Sprugel KH, Fox NE, Sabath DE, Kaushansky K. Murine thrombopoietin mRNA levels are modulated by platelet count. Blood. 1995; 86(10): 3668-3675.
2. Kaushansky K. The molecular mechanisms that control thrombopoiesis. J Clin Invest. 2005; 115(12): 3339-3347.
3. Kaushansky K. Determinants of platelet number and regulation of thrombopoiesis. Hematology Am Soc Hematol Educ Program. 2009; 2009: 147-152.
4. Kuter DJ. Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia. Annu Rev Med. 2009; 60: 193-206.
5. Machlus KR, Thon JN, Italiano JE Jr. Interpreting the developmental dance of the megakaryocyte: A review of the cellular and molecular processes mediating platelet formation. Br J Haematol. 2014; 165(2): 227-236.
6. Bender M, Giannini S, Grozovsky R, et al. Dynamin 2-dependent endocytosis is required for normal megakaryocyte development in mice. Blood. 2015; 125(6): 1014-1024.
7. Zhang L, Orban M, Lorenz M, et al. A novel role of sphingosine 1-phosphate receptor S1pr1 in mouse thrombopoiesis. J Exp Med. 2012; 209(12): 2165-2181.
8. Kaushansky K. Thrombopoiesis. Semin Hematol. 2015; 52(1): 4-11.
9. Calvi LM, Adams GB, Weibrecht KW, et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature. 2003; 425(6960): 841-846.
10. Kiel MJ, Morrison SJ. Maintaining hematopoietic stem cells in the vascular niche. Immunity. 2006; 25(6): 862-864.
11. Junt T, Schulze H, Chen Z, et al. Dynamic visualization of thrombopoiesis within bone marrow. Science. 2007; 317(5845): 1767-1770.
12. Malara A, Currao M, Gruppi C, et al. Megakaryocytes contribute to the bone marrow-matrix environment by expressing fibronectin, type IV collagen, and laminin. Stem Cells. 2014; 32(4): 926-937.
13. Hodohara K, Fujii N, Yamamoto N, Kaushansky K. Stromal cell-derived factor-1 (SDF-1) acts together with thrombopoietin to enhance the development of megakaryocytic progenitor cells (CFU-MK). Blood. 2000; 95(3): 769-775.
14. Sugiyama T, Kohara H, Noda M, Nagasawa T. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity. 2006; 25(6): 977-988.
15. Broudy VC. Stem cell factor and hematopoiesis. Blood. 1997; 90(4): 1345-1364.
16. Broudy VC, Lin NL, Kaushansky K. Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro. Blood. 1995; 85(7): 1719-1726.
17. Avraham H, Cowley S, Chi SY, Jiang S, Groopman JE. Characterization of adhesive interactions between human endothelial cells and megakaryocytes. J Clin Invest. 1993; 91(6): 2378-2384.
18. Fox NE, Kaushansky K. Engagement of integrin alpha4beta1 enhances thrombopoietin-induced megakaryopoiesis. Exp Hematol. 2005; 33(1): 94-99.
19. Ku H, Yonemura Y, Kaushansky K, Ogawa M. Thrombopoietin, the ligand for the Mpl receptor, synergizes with steel factor and other early acting cytokines in supporting proliferation of primitive hematopoietic progenitors of mice. Blood. 1996; 87(11): 4544-4551.
20. Sitnicka E, Lin N, Priestley GV, et al. The effect of thrombopoietin on the proliferation and differentiation of murine hematopoietic stem cells. Blood. 1996; 87(12): 4998-5005.
21. Qian H, Buza-Vidas N, Hyland CD, et al. Critical role of thrombopoietin in maintaining adult quiescent hematopoietic stem cells. Cell Stem Cell. 2007; 1(6): 671-684.
22. Arai F, Yoshihara H, Hosokawa K, et al. Niche regulation of hematopoietic stem cells in the endosteum. Ann N Y Acad Sci. 2009; 1176: 36-46.
23. Balduini A, Pallotta I, Malara A, et al. Adhesive receptors, extracellular proteins and myosin IIA orchestrate proplatelet formation by human megakaryocytes. J Thromb Haemost. 2008; 6(11): 1900-1907.
24. Kuter DJ, Rosenberg RD. The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfaninduced thrombocytopenia in the rabbit. Blood. 1995; 85(10): 2720-2730.
25. Cohen-Solal K, Villeval JL, Titeux M, Lok S, Vainchenker W, Wendling F. Constitutive expression of Mpl ligand transcripts during thrombocytopenia or thrombocytosis. Blood. 1996; 88(7): 2578-2584.
26. Fielder PJ, Gurney AL, Stefanich E, et al. Regulation of thrombopoietin levels by c-mplmediated binding to platelets. Blood. 1996; 87(6): 2154-2161.
27. Shinjo K, Takeshita A, Nakamura S, et al. Serum thrombopoietin levels in patients correlate inversely with platelet counts during chemotherapy-induced thrombocytopenia. Leukemia. 1998; 12(3): 295-300.
28. Engel C, Loeffler M, Franke H, Schmitz S. Endogenous thrombopoietin serum levels during multicycle chemotherapy. Br J Haematol. 1999; 105(3): 832-838.
29. Ihara K, Ishii E, Eguchi M, et al. Identification of mutations in the c-mpl gene in congenital amegakaryocytic thrombocytopenia. Proc Natl Acad Sci USA. 1999; 96(6): 3132-3136.
30. Ballmaier M, Germeshausen M, Schulze H, et al. c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia. Blood. 2001; 97(1): 139-146.
31. Ballmaier M, Schulze H, Strauss G, et al. Thrombopoietin in patients with congenital thrombocytopenia and absent radii: Elevated serum levels, normal receptor expression, but defective reactivity to thrombopoietin. Blood. 1997; 90(2): 612-619.
32. Schrezenmeier H, Griesshammer M, Hornkohl A, et al. Thrombopoietin serum levels in patients with aplastic anaemia: Correlation with platelet count and persistent elevation in remission. Br J Haematol. 1998; 100(3): 571-576.
33. Gu J, Lu L, Xu R, Chen X. Plasma thrombopoietin levels in patients with aplastic anemia and idiopathic thrombocytopenic purpura. Chin Med J (Engl). 2002; 115(7): 983-986.
34. Ng AP, Kauppi M, Metcalf D, et al. Mpl expression on megakaryocytes and platelets is dispensable for thrombopoiesis but essential to prevent myeloproliferation. Proc Natl Acad Sci USA. 2014; 111(16): 5884-5889.
35. Meyer SC, Keller MD, Woods BA, et al. Genetic studies reveal an unexpected negative regulatory role for Jak2 in thrombopoiesis. Blood. 2014; 124(14): 2280-2284.
36. Kosugi S, Kurata Y, Tomiyama Y, et al. Circulating thrombopoietin level in chronic immune thrombocytopenic purpura. Br J Haematol. 1996; 93(3): 704-706.
37. Ichikawa N, Ishida F, Shimodaira S, Tahara T, Kato T, Kitano K. Regulation of serum thrombopoietin levels by platelets and megakaryocytes in patients with aplastic anaemia and idiopathic thrombocytopenic purpura. Thromb Haemost. 1996; 76(2): 156-160.
38. Wang JC, Chen C, Novetsky AD, Lichter SM, Ahmed F, Friedberg NM. Blood thrombopoietin levels in clonal thrombocytosis and reactive thrombocytosis. Am J Med. 1998; 104(5): 451-455.
39. Griesshammer M, Hornkohl A, Nichol JL, et al. High levels of thrombopoietin in sera of patients with essential thrombocythemia: Cause or consequence of abnormal platelet production? Ann Hematol. 1998; 77(5): 211-215.
40. Besancenot R, Chaligné R, Tonetti C, et al. A senescence-like cell-cycle arrest occurs during megakaryocytic maturation: Implications for physiological and pathological megakaryocytic proliferation. PLoS Biol. 2010; 8(9): E1000476.
41. Pecquet C, Diaconu CC, Staerk J, et al. Thrombopoietin receptor down-modulation by JAK2 V617F: Restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes. Blood. 2012; 119(20): 4625-4635.
42. Sungaran R, Chisholm OT, Markovic B, Khachigian LM, Tanaka Y, Chong BH. The role of platelet alpha-granular proteins in the regulation of thrombopoietin messenger RNA expression in human bone marrow stromal cells. Blood. 2000; 95(10): 3094-3101.
43. Mouthon MA, Vandamme M, Gourmelon P, Vainchenker W, Wendling F. Preferential liver irradiation enhances hematopoiesis through a thrombopoietin-independent mechanism. Radiat Res. 1999; 152(4): 390-397.
44. Sungaran R, Markovic B, Chong BH. Localization and regulation of thrombopoietin mRNa expression in human kidney, liver, bone marrow, and spleen using in situ hybridization. Blood. 1997; 89(1): 101-107.
45. Qian S, Fu F, Li W, Chen Q, de Sauvage FJ. Primary role of the liver in thrombopoietin production shown by tissue-specific knockout. Blood. 1998; 92(6): 2189-2191.
46. Wolber EM, Ganschow R, Burdelski M, Jelkmann W. Hepatic thrombopoietin mRNA levels in acute and chronic liver failure of childhood. Hepatology. 1999; 29(6): 1739-1742.
47. McIntosh B, Kaushansky K. Transcriptional regulation of bone marrow thrombopoietin by platelet proteins. Exp Hematol. 2008; 36(7): 799-806.
48. Wolber EM, Fandrey J, Frackowski U, Jelkmann W. Hepatic thrombopoietin mRNA is increased in acute inflammation. Thromb Haemost. 2001; 86(6): 1421-1424.
49. Kaser A, Brandacher G, Steurer W, et al. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: Role in inflammatory thrombocytosis. Blood. 2001; 98(9): 2720-2725.
50. Stone RL, Nick AM, McNeish IA, et al. Paraneoplastic thrombocytosis in ovarian cancer [published correction appears in N Engl J Med. 2012; 367(18): 1768]. N Engl J Med. 2012; 366(7): 610-618.
51. Cerutti A, Custodi P, Duranti M, Noris P, Balduini CL. Thrombopoietin levels in patients with primary and reactive thrombocytosis. Br J Haematol. 1997; 99(2): 281-284.
52. Wolber EM, Jelkmann W. Interleukin-6 increases thrombopoietin production in human hepatoma cells HepG2 and Hep3B. J Interferon Cytokine Res. 2000; 20(5): 499-506.
53. Burmester H, Wolber EM, Freitag P, Fandrey J, Jelkmann W. Thrombopoietin production in wildtype and interleukin-6 knockout mice with acute inflammation. J Interferon Cytokine Res. 2005; 25(7): 407-413.
54. Rumjantseva V, Hoffmeister KM. Novel and unexpected clearance mechanisms for cold platelets. Transfus Apheresis Sci. 2010; 42(1): 63-70.
55. Hoffmeister KM. The role of lectins and glycans in platelet clearance. J Thromb Haemost. 2011; 9(suppl 1): 35-43.
56. Grozovsky R, Begonja AJ, Liu K, et al. The Ashwell-Morell receptor regulates hepatic thrombopoietin production via JAK2-STAT3 signaling. Nat Med. 2015; 21(1): 47-54.
57. Jansen AJ, Josefsson EC, Rumjantseva V, et al. Desialylation accelerates platelet clearance after refrigeration and initiates GPIba metalloproteinase-mediated cleavage in mice. Blood. 2012; 119(5): 1263-1273.
58. Alioglu B, Tasar A, Ozen C, Selver B, Dallar Y. An experience of oseltamivir phosphate (tamiflu™) in a pediatric patient with chronic idiopathic thrombocytopenic purpura: A case report. Pathophysiol Haemost Thromb. 2010; 37(2-4): 55-58.
59. Shao L, Wu Y, Zhou H, et al. Successful treatment with oseltamivir phosphate in a patient with chronic immune thrombocytopenia positive for anti-GPIb/IX autoantibody. Platelets. 2015; 26(5): 495-497.
60. Jansen AJ, Peng J, Zhao HG, Hou M, Ni H. Sialidase inhibition to increase platelet counts: A new treatment option for thrombocytopenia. Am J Hematol. 2015; 90(5): E94-E95.
61. Sørensen AL, Rumjantseva V, Nayeb-Hashemi S, et al. Role of sialic acid for platelet life span: Exposure of beta-galactose results in the rapid clearance of platelets from the circulation by asialoglycoprotein receptor-expressing liver macrophages and hepatocytes. Blood. 2009; 114(8): 1645-1654.
62. Grewal PK, Uchiyama S, Ditto D, et al. The Ashwell receptor mitigates the lethal coagulopathy of sepsis. Nat Med. 2008; 14(6): 648-655.
63. Grewal PK. The Ashwell-Morell receptor. Methods Enzymol. 2010; 479: 223-241.
64. Rumjantseva V, Grewal PK, Wandall HH, et al. Dual roles for hepatic lectin receptors in the clearance of chilled platelets. Nat Med. 2009; 15(11): 1273-1280.
65. Grewal PK, Aziz PV, Uchiyama S, et al. Inducing host protection in pneumococcal sepsis by preactivation of the Ashwell-Morell receptor. Proc Natl Acad Sci USA. 2013; 110(50): 20218-20223.
66. Crook M. Platelet sialic acid and its significance to platelet life-spans. Platelets. 1990; 1(3): 167.
67. Crook M. Sialic acid: Its importance to platelet function in health and disease. Platelets. 1991; 2(1): 1-10.
68. Reimers HJ, Greenberg J, Cazenave JP, Packham MA, Mustard JF. Experimental modification of platelet survival. Adv Exp Med Biol. 1977; 82: 231-233.
69. Eulenfeld R, Dittrich A, Khouri C, et al. Interleukin-6 signalling: More than Jaks and STATs. Eur J Cell Biol. 2012; 91(6-7): 486-495.
70. Levine RL, Gilliland DG. Myeloproliferative disorders. Blood. 2008; 112(6): 2190-2198.
71. LaFave LM, Levine RL. JAK2 the future: Therapeutic strategies for JAK-dependent malignancies. Trends Pharmacol Sci. 2012; 33(11): 574-582.
72. Park SO, Wamsley HL, Bae K, et al. Conditional deletion of Jak2 reveals an essential role in hematopoiesis throughout mouse ontogeny: Implications for Jak2 inhibition in humans. PLoS One. 2013; 8(3): E59675.
73. Grisouard J, Hao-Shen H, Dirnhofer S, Wagner KU, Skoda RC. Selective deletion of Jak2 in adult mouse hematopoietic cells leads to lethal anemia and thrombocytopenia. Haematologica. 2014; 99(4): E52-e54.
74. Fallon RJ, Danaher M, Saxena A. The asialoglycoprotein receptor is associated with a tyrosine kinase in HepG2 cells. J Biol Chem. 1994; 269(43): 26626-26629.
75. Alonzi T, Maritano D, Gorgoni B, Rizzuto G, Libert C, Poli V. Essential role of STAT3 in the control of the acute-phase response as revealed by inducible gene inactivation [correction of activation] in the liver. Mol Cell Biol. 2001; 21(5): 1621-1632.
76. Lesurtel M, Graf R, Aleil B, et al. Platelet-derived serotonin mediates liver regeneration. Science. 2006; 312(5770): 104-107.
77. Moh A, Iwamoto Y, Chai GX, et al. Role of STAT3 in liver regeneration: Survival, DNA synthesis, inflammatory reaction and liver mass recovery. Lab Invest. 2007; 87(10): 1018-1028.
78. Dalton SR, Lee SM, King RN, et al. Carbon tetrachloride-induced liver damage in asialoglycoprotein receptor-deficient mice. Biochem Pharmacol. 2009; 77(7): 1283-1290.
79. Sullivan MT, Wallace EL. Blood collection and transfusion in the United States in 1999. Transfusion. 2005; 45(2): 141-148.
80. Heddle NM, Klama L, Frassetto R, O'Hoski P, Leaman B. A retrospective study to determine the risk of red cell alloimmunization and transfusion during pregnancy. Transfusion. 1993; 33(3): 217-220.
81. Silliman CC, Boshkov LK, Mehdizadehkashi Z, et al. Transfusion-related acute lung injury: Epidemiology and a prospective analysis of etiologic factors. Blood. 2003; 101(2): 454-462.
82. Dunbar NM, Ornstein DL, Dumont LJ. ABO incompatible platelets: Risks versus benefit. Curr Opin Hematol. 2012; 19(6): 475-479.
83. Karpatkin S, Shulman S. Asialo platelets enhance thrombopoiesis. Trans Assoc Am Physicians. 1980; 93: 244-250.
84. Hoffmeister KM, Felbinger TW, Falet H, et al. The clearance mechanism of chilled blood platelets. Cell. 2003; 112(1): 87-97.
85. Petty HR, Todd RF III. Receptor-receptor interactions of complement receptor type 3 in neutrophil membranes. J Leukoc Biol. 1993; 54(5): 492-494.
86. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm. Cell. 1994; 76(2): 301-314.
87. Xia Y, Borland G, Huang J, et al. Function of the lectin domain of Mac-1/complement receptor type 3 (CD11b/CD18) in regulating neutrophil adhesion. J Immunol. 2002; 169(11): 6417-6426.
88. Simon DI, Chen Z, Xu H, et al. Platelet glycoprotein ibalpha is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18). J Exp Med. 2000; 192(2): 193-204.
89. Thornton BP, Vetvicka V, Pitman M, Goldman RC, Ross GD. Analysis of the sugar specificity and molecular location of the b-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18). J Immunol. 1996; 156(3): 1235-1246.
90. Josefsson EC, Gebhard HH, Stossel TP, Hartwig JH, Hoffmeister KM. The macrophage alphaMbeta2 integrin alphaM lectin domain mediates the phagocytosis of chilled platelets. J Biol Chem. 2005; 280(18): 18025-18032.
91. Badlou BA, Spierenburg G, Ulrichts H, Deckmyn H, Smid WM, Akkerman JW. Role of glycoprotein Ibalpha in phagocytosis of platelets by macrophages. Transfusion. 2006; 46(12): 2090-2099.
92. Ross GD. Role of the lectin domain of Mac-1/ CR3 (CD11b/CD18) in regulating intercellular adhesion. Immunol Res. 2002; 25(3): 219-227.
93. Hoffmeister KM, Josefsson EC, Isaac NA, Clausen H, Hartwig JH, Stossel TP. Glycosylation restores survival of chilled blood platelets. Science. 2003; 301(5639): 1531-1534.
94. Wandall HH, Hoffmeister KM, Sørensen AL, et al. Galactosylation does not prevent the rapid clearance of long-term, 4 degrees C-stored platelets. Blood. 2008; 111(6): 3249-3256.
95. Mason KD, Carpinelli MR, Fletcher JI, et al. Programmed anuclear cell death delimits platelet life span. Cell. 2007; 128(6): 1173-1186.
96. Debrincat MA, Josefsson EC, James C, et al. Mcl-1 and Bcl-x(L) coordinately regulate megakaryocyte survival. Blood. 2012; 119(24): 5850-5858.
97. Josefsson EC, James C, Henley KJ, et al. Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets. J Exp Med. 2011; 208(10): 2017-2031.
98. Zhang H, Nimmer PM, Tahir SK, et al. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ. 2007; 14(5): 943-951.
99. Liu ZJ, Hoffmeister KM, Hu Z, et al. Expansion of the neonatal platelet mass is achieved via an extension of platelet lifespan. Blood. 2014; 123(22): 3381-3389.
100. Cines DB, Bussel JB, Liebman HA, Luning Prak ET. The ITP syndrome: Pathogenic and clinical diversity. Blood. 2009; 113(26): 6511-6521.
101. McMillan R. The pathogenesis of chronic immune thrombocytopenic purpura. Semin Hematol. 2007; 44(4 suppl 5): S3-S11.
102. Li J, Callum JL, Lin Y, Zhou Y, Zhu G, Ni H. Severe platelet desialylation in a patient with glycoprotein Ib/IX antibody-mediated immune thrombocytopenia and fatal pulmonary hemorrhage. Haematologica. 2014; 99(4): E61-e63.
103. Li J, van der Wal DE, Zhu G, et al. Desialylation is a mechanism of Fc-independent platelet clearance and a therapeutic target in immune thrombocytopenia. Nat Commun. 2015; 6: 7737.
104. Semple JW, Italiano JE Jr, Freedman J. Platelets and the immune continuum. Nat Rev Immunol. 2011; 11(4): 264-274.